MX2022012671A - Vacuna terapeutica individualizada contra el cancer. - Google Patents

Vacuna terapeutica individualizada contra el cancer.

Info

Publication number
MX2022012671A
MX2022012671A MX2022012671A MX2022012671A MX2022012671A MX 2022012671 A MX2022012671 A MX 2022012671A MX 2022012671 A MX2022012671 A MX 2022012671A MX 2022012671 A MX2022012671 A MX 2022012671A MX 2022012671 A MX2022012671 A MX 2022012671A
Authority
MX
Mexico
Prior art keywords
anticancer vaccine
therapeutic anticancer
individualized therapeutic
vaccine
individualized
Prior art date
Application number
MX2022012671A
Other languages
English (en)
Inventor
Monika Sekelja
Agnete Brunsvik Fredriksen
Karoline Schjetne
Stine Granum
Original Assignee
Nykode Therapeutics ASA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nykode Therapeutics ASA filed Critical Nykode Therapeutics ASA
Publication of MX2022012671A publication Critical patent/MX2022012671A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001188—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

La presente invención se relaciona con una vacuna terapéutica individualizada contra el cáncer, métodos de tratamiento del cáncer donde se utiliza esa vacuna contra el cáncer, así como métodos para producir la vacuna.
MX2022012671A 2020-04-09 2021-04-09 Vacuna terapeutica individualizada contra el cancer. MX2022012671A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA202070221 2020-04-09
DKPA202070338 2020-05-26
PCT/EP2021/059353 WO2021205027A1 (en) 2020-04-09 2021-04-09 Individualized therapeutic anticancer vaccine

Publications (1)

Publication Number Publication Date
MX2022012671A true MX2022012671A (es) 2023-01-05

Family

ID=75539309

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022012671A MX2022012671A (es) 2020-04-09 2021-04-09 Vacuna terapeutica individualizada contra el cancer.

Country Status (11)

Country Link
US (1) US20230293650A1 (es)
EP (1) EP4132565A1 (es)
JP (1) JP2023522588A (es)
KR (1) KR20230004585A (es)
CN (1) CN115397462A (es)
AU (1) AU2021252155A1 (es)
BR (1) BR112022020277A2 (es)
CA (1) CA3172191A1 (es)
IL (1) IL297049A (es)
MX (1) MX2022012671A (es)
WO (1) WO2021205027A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3212592A1 (en) 2021-03-26 2022-09-29 Agnete Fredriksen Therapeutic combination for treating cancer
EP4333881A1 (en) 2021-05-03 2024-03-13 Nykode Therapeutics ASA Immunogenic constructs and vaccines for use in the prophylactic and therapeutic treatment of infectious diseases
KR20240019135A (ko) 2021-05-10 2024-02-14 니코데 테라퓨틱스 에이에스에이 작제물과 면역자극 화합물의 공동발현
WO2022238381A2 (en) 2021-05-10 2022-11-17 Nykode Therapeutics ASA Immunotherapy constructs for treatment of disease
WO2022238363A1 (en) 2021-05-10 2022-11-17 Nykode Therapeutics ASA Immunogenic constructs and vaccines for use in the prophylactic and therapeutic treatment of infectious diseases
WO2024092025A1 (en) 2022-10-25 2024-05-02 Nykode Therapeutics ASA Constructs and their use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013092875A1 (en) 2011-12-21 2013-06-27 Vaccibody As Vaccines against hpv
US10155031B2 (en) * 2012-11-28 2018-12-18 Biontech Rna Pharmaceuticals Gmbh Individualized vaccines for cancer
CA3008437A1 (en) 2016-01-08 2017-07-13 Vaccibody As Therapeutic anticancer neoepitope vaccine

Also Published As

Publication number Publication date
AU2021252155A1 (en) 2022-12-08
JP2023522588A (ja) 2023-05-31
CA3172191A1 (en) 2021-10-14
EP4132565A1 (en) 2023-02-15
BR112022020277A2 (pt) 2023-02-14
US20230293650A1 (en) 2023-09-21
CN115397462A (zh) 2022-11-25
WO2021205027A1 (en) 2021-10-14
IL297049A (en) 2022-12-01
KR20230004585A (ko) 2023-01-06

Similar Documents

Publication Publication Date Title
MX2022012671A (es) Vacuna terapeutica individualizada contra el cancer.
MX2019005465A (es) Metodo de tratamiento de un tumor inmunoterapeutico.
SA519401435B1 (ar) مركبات حلقية ثنائية النيوكليوتيد
PH12019500214A1 (en) Substituted thiazolo-pyridine compounds as malt1 inhibitors
PH12019501959A1 (en) Therapeutic rna
PH12020550901A1 (en) Macrocyclic compounds for treating disease
MX2022005775A (es) Compuestos terapeuticos y metodos de uso.
PH12019501119A1 (en) Pharmaceutical composition for preventing or treating breast cancer including crystalline polymorph of tetraarsenic hexoxide, and method for producing same
PH12019502363A1 (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
EA201291195A1 (ru) Усовершенствованная терапия рака на основе опухолеассоциированных антигенов, полученных из циклина d1
MX2018007844A (es) Derivado de benzopiperidina, metodo de preparacion del mismo y su uso medico del mismo.
PH12018502337A1 (en) Tetrahydropyrimidodiazepine and tetrahydropyridodiazepine compounds for treating pain and pain related conditions
MX2019013071A (es) Metodo de tratamiento inmunoterapeutico de un tumor.
MX2021016049A (es) Metodos de uso de inhibidores de rad51 para el tratamiento de cancer de pancreas.
MX2020012291A (es) Compuestos para el tratamiento de cancer de mama triple negativo y cancer de ovario.
MY173104A (en) Compounds from antrodia camphorata, method for preparing the same and use thereof
MX2021012201A (es) Adyuvante soluble en agua.
MX2013005697A (es) Analogos de bombesina marcados con lutecio 177, para radioterapia.
JOP20200090A1 (ar) عملية لتحضير بنزوثيوفين-2 يل بورونات
IL279168B (en) A process for the preparation of eribulin
MX2021012200A (es) Adyuvante soluble en agua y composición que contiene el mismo.
EA202192757A1 (ru) Способ лечения опухолей
AU2018251949A1 (en) Compounds, composition and uses thereof for treating cancer
EA202092122A1 (ru) Антитела против tip-1 и их применения
MX2019000542A (es) Derivados de pirazolilaminobenzimidazol como inhibidores de jak.